Ligand Pharmaceuticals LGND EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's EPS (basic)?
- Ligand Pharmaceuticals (LGND) reported EPS (basic) of -$0.67 in Q1 2026.
- How has Ligand Pharmaceuticals's EPS (basic) changed year-over-year?
- Ligand Pharmaceuticals's EPS (basic) increased by 69.7% year-over-year, from -$2.21 to -$0.67.
- What is the long-term trend for Ligand Pharmaceuticals's EPS (basic)?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's EPS (basic) has grown at a 15.5% compound annual growth rate (CAGR), from $3.57 to $6.36.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.